Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
B71-H52A4 | Human | Human B7-1 / CD80 Protein, Mouse IgG2a Fc Tag, low endotoxin | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
B71-H82E9 | Human | Biotinylated Human B7-1 / CD80 Protein, Avitag™,His Tag (recommended for biopanning) | ![]() |
![]() ![]() |
![]() ![]() |
B71-H82F2 | Human | Biotinylated Human B7-1 / CD80 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD0-M5228 | Mouse | Mouse B7-1 / CD80 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD0-C5252 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-1 / CD80 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD0-M5259 | Mouse | Mouse B7-1 / CD80 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD0-C52H3 | Cynomolgus / Rhesus macaque | Cynomolgus / Rhesus macaque B7-1 / CD80 Protein, His Tag (HPLC-verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
B71-H5228 | Human | Human B7-1 / CD80 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
B71-H5259 | Human | Human B7-1 / CD80 Protein, Fc Tag (HPLC-verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
Flow Cytometry assay shows that Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) can bind to 293 cell overexpressing human CTLA-4. The concentration of Human B7-1 is 1 μg/mL (Routinely tested).
FACS analysis shows that the binding of Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) to 293 overexpressing CTLA-4 was inhibited by increasing concentration of neutralizing Anti-human CTLA-4 antibody. The concentration of Human B7-1 is 1 μg /mL. The IC50 is 5.5 μg/mL (Routinely tested).
Immobilized Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (HPLC-verified) (Cat. No. CD8-H525a) on CM5 Chip can bind Human B7-1, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) with an affinity constant of 2.72 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Belatacept | LEA29Y; LEA-029; BMS-224818; L104EA29YIg | Approved | Bristol-Myers Squibb Company | Nulojix | EU | Rejection of renal transplantation | s:32:"Bristol-Myers Squibb Pharma Eeig"; | 2011-06-15 | Rejection of renal transplantation; Rejection of organ transplantation | Details |
Abatacept | BMS-188667; BMS-188667SC; ONO-4164SC; ONO-4164 | Approved | Bristol-Myers Squibb Company | Orencia | Mainland China | Arthritis, Rheumatoid | s:28:"Bristol-Myers Squibb Company"; | 2005-12-23 | Multiple Sclerosis; Crohn Disease; Nephrotic Syndrome; Muscular Diseases; Colitis, Ulcerative; Arthritis, Psoriatic; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic; Psoriasis; Polymyositis; Nephrosis, Lipoid; Lupus Nephritis; Arthritis, Juvenile; Sjogren's Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Dermatomyositis; Giant Cell Arteritis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech | Carcinoma, Non-Small-Cell Lung | Details |
rVV-740CTA vaccine (University Hospital Basel) | rVV-740CTA | Phase 1 Clinical | University Hospital Basel | Breast Neoplasms | Details |
Belatacept biosimilar (Alphamab) | KN-019 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Rejection of renal transplantation; Arthritis, Rheumatoid; Autoimmune Diseases | Details |
This web search service is supported by Google Inc.